A phase 2, multi-centre, randomised, doublemasked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
November 26, 2013
Principal Investigator: Paul A Edwards, MD
To evaluate how safe and effective the study drug known as GSK933776 is for patients with geographic atrophy.
Participants must have documented dry age related macular degeneration with geographic atrophy. They must be willing and able to participate in this 2 year study consisting of observation and treatment. All eligibility criteria must be met.
Mary K. Monk